{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:45:39Z","timestamp":1785775539699,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jctube.2026.100624","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:44:56Z","timestamp":1781023496000},"page":"100624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world challenges of 4-month rifapentine-moxifloxacin TB regimen: High hyperbilirubinemia in Thailand"],"prefix":"10.1016","volume":"44","author":[{"given":"Thanyanuch","family":"Sanchat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charoen","family":"Chuchottaworn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piamlarp","family":"Sangsayunh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunsanee","family":"Pungtaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirijit","family":"Rattanawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jctube.2026.100624_bb0005","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jctube.2026.100624_bb0010","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment","year":"2022"},{"issue":"1","key":"10.1016\/j.jctube.2026.100624_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.jctube.2026.100624_bb0020","author":"Division of AIDS"},{"issue":"4","key":"10.1016\/j.jctube.2026.100624_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae178","article-title":"Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco","volume":"11","author":"Louie","year":"2024","journal-title":"Open Forum Infect Dis."},{"issue":"7","key":"10.1016\/j.jctube.2026.100624_bb0030","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5588\/ijtld.24.0616","article-title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","volume":"29","author":"Galvis","year":"2025","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"10.1016\/j.jctube.2026.100624_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"10.1016\/j.jctube.2026.100624_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3201\/eid3103.241634","article-title":"Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes","volume":"31","author":"Kurbatova","year":"2025","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.jctube.2026.100624_bb0045","article-title":"Safety and Pharmacokinetics of Different Doses of Rifapentine in Patients with Susceptible Drug Tuberculosis: The Preliminary Result from a Randomized Controlled Trial (ORIENT Study) [abstract]","volume":"209","author":"Li","year":"2024","journal-title":"Am J Respir Crit Care Med."},{"issue":"3","key":"10.1016\/j.jctube.2026.100624_bb0050","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkaa490","article-title":"Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis","volume":"76","author":"Weiner","year":"2021","journal-title":"J Antimicrob Chemother."}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942600046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942600046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:55:49Z","timestamp":1785772549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240557942600046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"alternative-id":["S240557942600046X"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100624","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world challenges of 4-month rifapentine-moxifloxacin TB regimen: High hyperbilirubinemia in Thailand","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100624"}}